Beryl Drugs share price
You have to be logged in to add this to Watchlist.- ₹20.29(-3.93%)April 30, 2025 15:25:40 PM IST
- NSE
- BSE
- Vol : 4.52K (NSE + BSE)Last 20 day avg : 1.97 K
Beryl Drugs is trading -3.93% lower at Rs 20.29 as compared to its last closing price. Beryl Drugs has been trading in the price range of 21.12 & 20.07. Beryl Drugs has given -41.58% in this year & -8.17% in the last 5 days. Beryl Drugs has TTM P/E ratio 227.40 as compared to the sector P/E of 28.04.The company posted a net profit of 0.05 Crores in its last quarter.Listed peers of Beryl Drugs include Decipher Labs (2.31%), Unjha Formulations (-6.95%), Beryl Drugs (-3.93%).The Mutual Fund holding in Beryl Drugs was at -% in . The MF holding has - from the last quarter. The FII holding in Beryl Drugs was at -% in . The FII holding has - from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on Apr 30, 2025, 10:50 AM UTC
- Dividend YieldLower than industry0.00Annual dividends as a percentage of the stock price.
- P/BHigher than historical values1.20The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values132.86Price-to-earnings ratio based on trailing 12-month earnings
- BetaHigh volatility1.57Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.57The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable
The company's revenue fell during December quarter by 30.35% from Rs 7.62 crore to Rs 5.31 crore, year-on-year- The company's profit declined by 83.23% year-on-year during the December quarter, dropping from Rs 0.31 crore to Rs 0.05 crore
- The debt to equity of the company is higher than the industry median
- Earnings are insufficient to cover the interest expenses on outstanding debt
- R1
- 23.41
- R2
- 25.77
- R3
- 27.05
- S1
- 19.77
- S2
- 18.49
- S3
- 16.13
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Decipher Labs | Bearish | 11.52 | 2.31 | 11.63 | - | 0.54 | - | - |
| Unjha Formulations | Bearish | 22.61 | -6.95 | 10.13 | 41.16 | 4.19 | - | - |
| Beryl Drugs | Bearish | 20.29 | -3.93 | 10.29 | 14.81 | 1.26 | - | 26.94 |
| Vivanza Biosciences | Bearish | 2.22 | -2.20 | 8.88 | 16.36 | 1.97 | - | 57.82 |
| Ortin Global | Bearish | 10.79 | 0.37 | 8.43 | - | 3.19 | - | 63.82 |
- Promoter(s) does not have a high stake in the company
- FIIs are not invested in this company
- Mutual Funds are not invested in this company.
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-02-08 | Quarterly Results |
| 2024-11-13 | Quarterly Results |
| 2024-08-09 | Quarterly Results |
| 2024-05-30 | Audited Results |
| 2024-04-20 | Others |
- IndustryBiotechnology & Drugs
- ISININE415H01017
- BSE Code524606
- NSE Code
Beryl Drugs is trading at 20.29 as on Wed Apr 30 2025 09:55:40. This is -3.93% lower as compared to its previous closing price of 21.12.
The market capitalization of Beryl Drugs is 10.29 Cr as on Wed Apr 30 2025 09:55:40.
The 52 wk high for Beryl Drugs is 46.00 whereas the 52 wk low is 20.27
Beryl Drugs can be analyzed on the following key metrics -
- TTM P/E: 227.40
- Sector P/E: 28.04
- Dividend Yield: 0.00%
- D/E ratio: -
Beryl Drugs reported a net profit of 0.77 Cr in 2024.